We are leveraging advances in open-source data and AI to repurpose existing drugs and GRAS compounds as antivirals, and to combine several weak antivirals into powerful combinations.

Read our white paper: “Benchmarking open-source tools for in silico antiviral drug discovery”. Daniel C. Elton and Preston W. Estep, arXiv pre-print, May 2026.

More details coming soon.